PHP15: IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS  by Kleinstiver, P & Baladi, JF
Abstracts 477
RESULTS: Approximately 10 studies matched the selec-
tion criteria, all published in 1994 or later. The safety mea-
sures evaluated were donor screening, viral inactivation of
frozen plasma, and single-donor versus random-donor
platelet collection. Cost-effectiveness ranged from cost sav-
ings for screening donors for hepatitis C antibodies, to sev-
eral million US$ per QALY gained as a result of screening
donors for HIV using p-24 or nucleic-acid tests. Cost-
effectiveness of viral inactivation of plasma and of shifting
to single-donor platelet collection strongly depends on the
patient population. For example, US$100,000-200,000
per QALY gained for coronary artery bypass graft and
US$400,000-500,000 for cancer patients.
CONCLUSIONS: In the USA and Canada, thresholds
for acceptable cost-effectiveness are US$50,000 and
Can$20,000-100,000 (US$13,000-67,000) per QALY
gained. For the Netherlands, the threshold has recently been
defined at Dfl40,000 per life-year gained (EUR18,000,
US$16,000). Preliminary results from our European
model applied to the recently introduced nucleic-acid
testing of Dutch donors for HIV indicate cost-effective-
ness ratios of US$100,000 per life-year gained and above.
Most cost-effectiveness ratios for interventions in trans-
fusion safety are beyond currently accepted thresholds
for cost-effectiveness. This may imply that different thresh-
olds for cost-effectiveness apply when making decisions
about the introduction of new technologies that enhance
transfusion safety.
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OBJECTIVES: Pharmaceutical expenditures in Greece in-
crease by approximately 18% annually. To curtail spend-
ing, government has recently cut prices and introduced a
positive drug list. The short-term impact of these mea-
sures led the government to propose new drug list criteria
and submission of pharmacoeconomic studies already
submitted in other countries for new products. We ad-
dress the current status of pharmacoeconomics research
and discuss future developments in Greece.
METHODS: We reviewed all available studies published
in Greek or English, to assess methodological problems.
We reviewed current developments in the public and pri-
vate sectors and policy documents to assess the potential
for future use of pharmacoeconomics in drug policy.
Case studies provide support for proposed conclusions.
RESULTS: Methodological quality is generally poor.
Cost minimization is the preferred technique although
differences in efficacy are not properly assessed. Few
studies accurately describe resource consumption and
costing methodologies. Modeling assumptions are weak,
due to absence of epidemiological and health-care utiliza-
tion data. Little emphasis is given to prospective clinical
studies. Thye societal perspective is rarely used—the
health system perspective prevails. Little experience exists
in QoL measurement and cost-utility techniques. Sensi-
tivity analyses are rarely performed. The pharmaceutical
industry is the major driving force for pharmacoeco-
nomic research despite minimal use in pricing and reim-
bursement decisions and weak endorsement by some. In-
dustry use is mainly for supporting marketing and sales
strategies. The government is hesitant to apply pharma-
coeconomics widely in pricing and reimbursement due to
perceived lack of expertise despite disappointment with
pricing controls. Recent health-care reforms may alter
current mindset. Medical professionals are increasingly
receptive of pharmacoeconomics research but place little
value on modeling approaches.
CONCLUSIONS: Pharmacoeconomics in Greece must
improve methodological standards. This is a task for
both industry and government. Wider application in pric-
ing and reimbursement is a still a matter for debate.
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OBJECTIVE: Companies producing innovative products
typically terminate all advertising and promotion (A&P)
of branded products once generics have been launched.
This may be prudent since branded sales often decline by
50% to 75% in the first year following generic introduc-
tion. Our primary hypothesis was that companies, which
cease A&P on products about to be genericized, might in-
directly hasten the decline in sales of branded products by
increasing the relative share of the competitors’ promo-
tional activity. We further hypothesized that this alter-
ation in A&P may result in a shift to more expensive
competitive compounds, thereby negating any savings re-
alized from the generic compound.
METHODS: Three therapeutic categories (selective sero-
tonin re-uptake inhibitors (SSRIs), anti-lipidemics [statins]
and anti-ulcer compounds) were selected for a compre-
hensive analysis of sales data.
RESULTS: A trend towards an increase in growth of
competitive, branded compounds, following the introduc-
tion of a generic drug, appeared to be true for both statins
and SSRIs. Aggregate fluoxetine sales and/or reimburse-
ments declined significantly in Ontario (18.5%), Que-
bec (34.9%) and nationally (42.8%) following the in-
troduction of generic fluoxetine. Although the overall
category growth for SSRIs was 49.2%, 117.0% and
97.5% for Ontario, Quebec and Canada respectively,
during the same time period, both paroxetine and sertra-
line experienced a much faster growth rate. Following the
introduction of generic lovastatin, aggregate lovastatin
sales and/or reimbursement declined 39.0% in Ontario,
32.4% in Quebec and 40.1% nationally. Coincidentally
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with the introduction of generic lovastatin, atorvastatin
was launched and appeared to benefit from the decline in
A&P of lovastatin, as did pravastatin.
CONCLUSION: Evidence exists in each of the three mar-
kets reviewed to support the hypothesis for two of the
three therapeutic classes investigated. There appeared to be
a trend toward a significant increase in growth in competi-
tive branded compounds in both the SSRI and statin mar-
kets following introduction of the first generic drug.
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OBJECTIVE: Responsiveness has been pointed out by
the WHO as one of the main objectives for any health
system. Portugal, despite being in the expected place
among other countries and taking into account the level
of health of its citizens and the level of cultural and eco-
nomic development, is placed very low when responsive-
ness is considered. This study aimed at assessing the per-
ceptions of Portuguese citizens as users of primary care.
METHODS: A representative sample of users of all
health centers within an entire health region was asked
about how responsive primary care was. Users’ satisfac-
tion was measured via the Portuguese version of the
Europep questionnaire. This instrument mainly measures
relationship and communication, medical care, informa-
tion and support, continuity and cooperation, and service
organization. Four thousand answers were received
(40.5% response rate) from a survey performed in major
urban and rural areas.
RESULTS: 62% of users were female with an average
age of 47 years, 50% with low or very low education and
with an average of 5.2 visits per year. Approximately
12% felt a good or excellent quality of life and 71%
mentioned having a chronic disease. The results indicated
a higher satisfaction from users about the doctor-patient
relationship, both in caring (76%) and curing (70%) as-
pects. The areas related to the organization were, how-
ever, very penalized by patients (49%). Open-ended
questions revealed the same profile but provided greater
insight about the source of the dissatisfaction. The results
were also compared taking into account gender, age, edu-
cation and quality of life.
CONCLUSION: Paraphrasing Deming, it is common to
observe a majority of areas of concern among the organi-
zation’s management and administration. Health-care
setting is not an exception. After this diagnosis, based on
patients’ views, it is advised to look with more attention
at these aspects.
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OBJECTIVE: To derive one European EQ-5D value set
that can be used to calculate a European EQ-5D health-
status index based on preferences of the general public.
EQ-5D from the EuroQol Group is an instrument capa-
ble of summarizing health-related quality of life into a
single index value by applying general population prefer-
ence weights. Values have been derived for EQ-5D health
states using the visual analogue scale (VAS) or time trade-
off (TTO) approaches. The option to derive European
VAS- and TTO-based EQ-5D health status models has
been investigated.
METHODS: Multi-level analysis was performed on
82,910 observations of VAS values derived from 11 stud-
ies in different countries and on 50,780 TTO observa-
tions derived from three studies.
RESULTS: After controlling for background variables, it
was found that the country of origin of the study did not
have a consistent effect on the VAS valuations of the
EQ-5D health states. The evidence shows that European
countries may share a similar value system for VAS rat-
ings of health states. All coefficients have the right signs,
while the values all differ from zero and produce values
that are plausible. The explained variance by the model
describing VAS values is 74.5 %. Multilevel analysis of
the TTO valuations revealed that on average the German
values are 20 % higher than the English and Spanish val-
ues. Half of this difference can be explained by control-
ling for background variables.
CONCLUSIONS: These results suggest that while more
work is required to establish a European TTO-based
health-status index, a European VAS-based EQ-5D health-
status index is viable. A European health-status index
has two advantages: i) An index would not have to be
generated separately for each European country, and ii)
the index can be used in multi-national randomized clini-
cal trials examining cost effectiveness of pharmaceutical
products.
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OBJECTIVE: To assess the number and type of pharma-
ceutical interventions for medical wards during the initial
three-month period of a new clinical pharmacy service.
METHODS: The clinical pharmacist participated in daily
rounds and other ward activities to review patient data
and determine necessary interventions. A computerized
evaluation and intervention form was developed to in-
clude patients’ demographic details, diagnoses, labora-
tory results, medication use and the reason for the inter-
